Key takeaways
- Gusev and colleagues’ 2018 study randomly divided 110 adults in rehabilitation into Semax and no-Semax groups; it had no placebo, and the paper does not say how the randomisation was done.
- Panikratova and colleagues’ 2020 study enrolled 52 healthy people across three groups and measured resting brain activity, not health outcomes.
- The 5- and 20-minute brain scans in the 2020 study tell you when researchers looked, not whether or when a meaningful effect begins.
- In its July 2026 briefing, FDA staff found insufficient evidence of effectiveness for the three proposed uses they could evaluate.
01Which Semax studies randomised people or used a placebo?
Two features make a comparison in people stronger: random assignment, and a placebo group so that participants cannot tell who received the peptide. Among the Semax studies cited here, one has the first and one has the second; we could verify none that has both.
Gusev and colleagues (2018) divided 110 adults in rehabilitation into early and late rehabilitation groups. Their Methods say each group was randomly split into a Semax and a no-Semax subgroup, without saying how. The no-Semax subgroups received no placebo. Researchers measured muscle strength, independence in daily activities and the blood level of a protein called brain-derived neurotrophic factor.
Panikratova and colleagues (2020) had a placebo group beside Semax and Selank groups, in 52 healthy people, but the abstract does not say how participants were assigned. They measured resting brain activity on scans, not a health outcome.
FDA staff also list a 1996 paper by Kaplan and colleagues with 19 healthy men. FDA’s summary does not describe its design, and we could not open the paper’s methods, so this page gives it no tier.
02What each study measured
Read across for the model, sample size, year, measure, and main limitation. Here, n is the number of participants or animals in the comparison described, not necessarily the number in the Semax group.
| Measure area | Study and year | Model and n | Design and tier | What was measured | Main limitation |
|---|---|---|---|---|---|
| Brain activity at rest | Panikratova et al., 2020 | Human: 52 healthy participants across all groups | Semax, Selank, or placebo; T2 here because the abstract does not describe assignment | How closely activity in different brain regions tracked together on functional magnetic resonance imaging | Brain scans, not a health outcome. Material sold online is not established to be the same as the study material. |
| Physical function and a blood marker | Gusev et al., 2018 | Human: 110 adults in rehabilitation | Early or late rehabilitation, each with a Semax and a no-Semax group; T2 here because the paper does not explain how it randomized participants | Muscle strength, independence in daily activities, and blood levels of brain-derived neurotrophic factor, a protein measured as a marker | No placebo comparison. The blood marker and the functional scores are different measures. Material sold online is not established to be the same as the study material. |
| Pain ratings | Koroleva et al., 1996 | Human: 37 adults across the study populations | Open-label, no control group; T2 | Among the measures: pain ratings and electrical responses to facial nerve stimulation | Without a control group, the study cannot separate the contribution of Semax from other explanations. Material sold online is not established to be the same as the study material. |
| Muscle electrical activity and quality of life | Serdiuk et al., 2007 | Human: 27 adults | Open-label, sequential groups as described in the abstract; T2 here | Among the measures: muscle electrical activity, functional ratings, and quality of life | The abstract does not explain random assignment despite PubMed’s randomized-trial label. Material sold online is not established to be the same as the study material. |
| Gene activity in brain tissue | Medvedeva et al., 2014 | Animal: male rats, at least 5 at each sampling time | Controlled animal experiment; T3 | Activity of genes in brain tissue after an experimentally blocked artery | Gene activity in this rat model is not evidence of an effect in people. |
| Enzyme activity in serum | Kost et al., 2001 | Laboratory: human serum outside the body; sample count not stated in the abstract | Test-tube experiment; T4 | Activity of enzymes that break down peptides called enkephalins | Human serum in a test tube is not evidence of an effect in people. |
03What the study clock can tell you
In Panikratova and colleagues’ 2020 study, the clock marked when the researchers scanned 52 healthy participants across the Semax, Selank, and placebo groups. It did not mark when a meaningful effect began.
- BaselineFirst scan
The researchers recorded resting brain activity for comparison.
- 5 minutesSecond scan
This was the first follow-up imaging time point, not a measure of when participants noticed a change.
- 20 minutesThird scan
This was the last imaging time point in the study, not a measure of how long a meaningful effect would last.
There is a separate question: how Semax levels change in the body over time. That is what a pharmacokinetic study measures. FDA staff reported that their review did not find a human pharmacokinetic study of Semax, including Semax acetate. A scan time is not a measurement of the peptide’s level in the body.
04How to read the evidence
If you searched “semax benefits”, these three checks show what any Semax study can and cannot tell you.
A placebo comparison and a comparison against rehabilitation alone answer different questions. Read how people were assigned, not just how many groups the paper lists.
A brain scan, a blood marker, and a score for independence in daily activities are not interchangeable. Ask which one the researchers actually recorded before drawing a conclusion.
A certificate of analysis documents tests on a sample. It does not establish a health outcome or show that the sample is equivalent to material used in a study. See how to read a certificate of analysis.
For the peptide’s identity and regulatory background, see the Semax guide.
05What we don’t know
- Whether narrow measures tell us anything broader. A blood marker, a strength score and a brain scan in small groups do not show how Semax would affect other people, settings or measures.
- Whether or when a meaningful effect occurs, and how long it lasts. The 2020 scan schedule and the human pharmacokinetic gap identified by FDA staff do not give a reliable answer.
- Whether the proposed uses are supported. In its July 2026 briefing, FDA staff found insufficient evidence of effectiveness for the three uses they could evaluate. Only two references were available to them, with “insufficient details on the design and conduct of the studies”.
This is a plain-English summary of studies and public documents checked on 21 November 2026. It is not medical advice.